NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View

Key Takeaways NVO topped Q4 earnings and revenue estimates, but the stock fell as investors reacted to weak 2026 guidance.NVO faced pressure in diabetes and obesity care as GLP-1 momentum slowed amid intensifying competition.Novo Nordisk expects 2026 adjusted sales and operating profit to decline 5-13% at the constant exchange rate.Novo Nordisk A/S (NVO) reported adjusted fourth-quarter 2025 earnings of $1 per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 90 cents. The compan ...